Mirtazapine Sandoz

Mirtazapine, the active ingredient in Mirtazapine Sandoz, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is indicated for the management of major depressive disorder in adult patients, helping to improve mood, sleep and appetite when prescribed by a qualified healthcare professional.

GNH USA supplies Mirtazapine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company’s robust logistics network enables timely delivery to diverse healthcare settings, adhering to stringent quality standards and supporting patient access to essential medicines.

Mirtazapine is a tetracyclic antidepressant used primarily in the treatment of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive disorder with anxiety features: helps alleviate anxiety accompanying depression. - Depression with insomnia or loss of appetite: can improve sleep quality and stimulate appetite.

Mirtazapine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Suicidal thoughts, especially early in treatment. - Severe hypersensitivity reactions, including rash or angioedema. - Hepatic dysfunction. - Seizures.

Before initiating therapy, clinicians should consider several safety aspects.

- Hepatic or renal impairment: assess function and adjust dose if necessary. - Suicidal ideation: monitor patients closely for worsening mood or emergent thoughts. - Cardiovascular disease: use caution in patients with arrhythmias or conduction disorders. - Concomitant CNS depressants: avoid excessive sedation by reviewing other sedating agents. - Discontinuation: taper gradually under medical supervision to reduce withdrawal risk. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Alcohol or other CNS depressants: additive sedation and respiratory depression. - Other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Antihistamines: may increase sedation. - Warfarin: monitor INR as mirtazapine can affect coagulation parameters.